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IMPORTANCE Refinement of criteria for multisystem inflammatory syndrome in children
(MIS-C) may inform efforts to improve health outcomes.
OBJECTIVE To compare clinical characteristics and outcomes of children and adolescents with
MIS-C vs those with severe coronavirus disease 2019 (COVID-19).
SETTING, DESIGN, AND PARTICIPANTS Case series of 1116 patients aged younger than 21 years
hospitalized between March 15 and October 31, 2020, at 66 US hospitals in 31 states. Final
date of follow-up was January 5, 2021. Patients with MIS-C had fever, inflammation,
multisystem involvement, and positive severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) reverse transcriptase–polymerase chain reaction (RT-PCR) or antibody test
results or recent exposure with no alternate diagnosis. Patients with COVID-19 had positive
RT-PCR test results and severe organ system involvement.
EXPOSURE SARS-CoV-2.
MAIN OUTCOMES AND MEASURES Presenting symptoms, organ system complications,
laboratory biomarkers, interventions, and clinical outcomes. Multivariable regression was
used to compute adjusted risk ratios (aRRs) of factors associated with MIS-C vs COVID-19.
RESULTS Of 1116 patients (median age, 9.7 years; 45% female), 539 (48%) were diagnosed with
MIS-C and 577 (52%) with COVID-19. Compared with patients with COVID-19, patients with
MIS-C were more likely to be 6 to 12 years old (40.8% vs 19.4%; absolute risk difference [RD],
21.4% [95% CI, 16.1%-26.7%]; aRR, 1.51 [95% CI, 1.33-1.72] vs 0-5 years) and non-Hispanic Black
(32.3% vs 21.5%; RD, 10.8% [95% CI, 5.6%-16.0%]; aRR, 1.43 [95% CI, 1.17-1.76] vs White).
Compared with patients with COVID-19, patients with MIS-C were more likely to have
cardiorespiratory involvement (56.0% vs 8.8%; RD, 47.2% [95% CI, 42.4%-52.0%]; aRR, 2.99
[95% CI, 2.55-3.50] vs respiratory involvement), cardiovascular without respiratory
involvement (10.6% vs 2.9%; RD, 7.7% [95% CI, 4.7%-10.6%]; aRR, 2.49 [95% CI, 2.05-3.02]
vs respiratory involvement), and mucocutaneous without cardiorespiratory involvement
(7.1% vs 2.3%; RD, 4.8% [95% CI, 2.3%-7.3%]; aRR, 2.29 [95% CI, 1.84-2.85] vs respiratory
involvement). Patients with MIS-C had higher neutrophil to lymphocyte ratio (median, 6.4 vs
2.7, P < .001), higher C-reactive protein level (median, 152 mg/L vs 33 mg/L; P < .001), and lower
platelet count (<150 ×103 cells/μL [212/523 {41%} vs 84/486 {17%}, P < .001]). A total of 398
patients (73.8%) with MIS-C and 253 (43.8%) with COVID-19 were admitted to the intensive
care unit, and 10 (1.9%) with MIS-C and 8 (1.4%) with COVID-19 died during hospitalization.
Among patients with MIS-C with reduced left ventricular systolic function (172/503, 34.2%) and
coronary artery aneurysm (57/424, 13.4%), an estimated 91.0% (95% CI, 86.0%-94.7%) and
79.1% (95% CI, 67.1%-89.1%), respectively, normalized within 30 days.
CONCLUSIONS AND RELEVANCE This case series of patients with MIS-C and with COVID-19
identified patterns of clinical presentation and organ system involvement. These patterns
may help differentiate between MIS-C and COVID-19.
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I nternational reports of coronavirus disease 2019 (COVID-19)–related severe complications in children began in April2020 when predominantly healthy children were hospi-
talized with cardiogenic shock or Kawasaki disease–like pre-
sentations temporally associated with severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2) infection.1-3 In mid-
May 2020, the Centers for Disease Control and Prevention
(CDC) published a case definition for multisystem inflamma-
tory syndrome in children (MIS-C) for disease surveillance.4
Criteria were intentionally broad to facilitate data capture for
diagnostic refinement. MIS-C was hypothesized to be mostly
postinfectious and distinct from COVID-19 because many pa-
tients’ respiratory specimens were SARS-CoV-2 negative and
MIS-C peaked after reported COVID-19 cases.5,6 Cardiovascu-
lar complications, such as ventricular dysfunction and coro-
nary artery aneurysms, triggered recommendations for im-
munomodulatory treatments, including intravenous
immunoglobulin (IVIG), corticosteroids, and biologics, and rec-
ommendations for intensive cardiac observation.5-9
Data on hospitalized children and adolescents with severe
acute COVID-19 are sparse, with few reports including more than
100 severe cases,5,8,10-15 and even fewer of these comparing
COVID-19 with MIS-C.8,11 As disease surveillance captured more
patients with MIS-C, phenotypes within MIS-C emerged, in-
cluding a predominantly respiratory phenotype with frequent
SARS-CoV-2–positive respiratory testing that potentially over-
lapped with severe acute COVID-19.8,14 A comparison of organ
involvement in MIS-C with severe acute COVID-19 in children
and adolescents, including the timing of resolution of cardio-
respiratory dysfunction, could help refine the MIS-C case defi-
nition to improve specificity for guiding use of immune thera-
pies, diagnostic testing, and follow-up.
Sentinel surveillance data captured on US patients hospi-
talized for 8 months were used to compare children and ado-
lescents diagnosed with MIS-C vs those with severe acute
COVID-19. Differences in the epidemiology, clinical character-
istics, types of complications, as well as hospital and postdis-
charge outcomes were compared between these groups to iden-
tify features distinguishing MIS-C from COVID-19.
Methods
Study Design and Participants
Forthiscaseseries,activesurveillancewasperformedintheOver-
coming COVID-19 network to identify children, adolescents, and
young adults (<21 years of age) with SARS-CoV-2–related illness
hospitalized during March 15 to October 31, 2020, from 31 states.5
The last date of follow-up for outcomes was January 5, 2021. The
study was approved by the central institutional review board at
Boston Children’s Hospital. The study was reviewed by the CDC
and was conducted consistent with applicable federal law and
CDC policy, which included a waiver of consent.16
Case Ascertainment and Definitions
Patients from the registry were included if they were hospital-
ized for acute illness at a participating site, were younger than
21 years old, and met criteria for MIS-C or severe acute COVID-19
(henceforth referred to as COVID-19), after adjudication by site
and coordinating center principal investigators. MIS-C criteria
were consistent with the CDC definition17 (Box 1). Patients with
COVID-19 had evidence of recent infection with SARS-CoV-2
based on having a positive RT-PCR test result and severe in-
volvement of 1 or more organ systems (Box 2). Sites that in-
cluded patients in other reports comparing COVID-19 and MIS-C
or reporting cardiac outcomes (n ≤191) are listed in eTable 1 in
the Supplement and include 168 patients with MIS-C we previ-
ously reported.5
We collected race and ethnicity information from hospital
medical records as reported by the site clinicians who cared for
the patients. Obesity was classified either by clinician diagno-
sis or, given underreporting,5 based on national reference stan-
dards for body mass index if aged at least 2 years.20 We classi-
fied nonobese patients without chronic diagnoses or use of
prescription medications as having no underlying conditions.
Mucocutaneous involvement was defined as presence of any of
the following: rash, inflammation of the oral mucosa, conjunc-
tivitis, and extremity findings, including erythema or edema of
the hands or feet, or periungual peeling. Echocardiographic find-
ings during hospitalization and postdischarge were obtained
from medical records. Left ventricular (LV) ejection fraction (EF)
was categorized as normal if EF was 55% or greater or noted to
be qualitatively normal, or as depressed if EF was less than 55%
or, in cases where EF was unavailable, based on the qualitative
grade of dysfunction. LV systolic function was further classi-
fied based on lowest EF as mildly depressed if 45% to 54%, mod-
erately depressed if 35% to 44%, and severely depressed if less
than 35%.21 Patients were classified as having no coronary ar-
tery aneurysm if the largest body surface area–adjusted z scores
in the proximal right coronary artery and proximal left anterior
descending coronary artery both were less than 2.5 or were re-
ported as qualitatively normal. Patients were classified as hav-
ing coronary artery aneurysms if either the right coronary ar-
tery or left anterior descending z score was 2.5 or greater or they
were described as having an aneurysm qualitatively.22 Aneu-
rysms were categorized as small if the z score was 2.5 to less than
5.0, medium if the z score was 5.0 to less than 10.0, and large or
giant if the z score was 10.0 or greater or an absolute dimension
of 8 mm or more.22 Each unique patient with 1 or more echo-
cardiogram reports that could be evaluated was classified on the
Key Points
Question How do the characteristics and outcomes of children
and adolescents with multisystem inflammatory syndrome in
children (MIS-C) compare with severe coronavirus disease 2019
(COVID-19)?
Findings In this case series that included 539 patients with MIS-C
and 577 patients with severe COVID-19, patients with MIS-C were
more likely than those with severe COVID-19 to be 6 to 12 years
old, be non-Hispanic Black, and have severe cardiovascular or
mucocutaneous involvement and more extreme inflammation.
Meaning The study findings suggest patterns of clinical
presentation and organ involvement that distinguish between
patients with MIS-C and severe acute COVID-19.
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basis of their worst-ever LVEF and highest coronary z score dur-
ing the illness. Respiratory support and cardiovascular pediat-
ric Severe Organ Failure Assessment scores based on vasoac-
tive agent support were also documented throughout
hospitalization (eTable 2 in the Supplement).23
Outcomes
We compared demographics (age, sex, race/ethnicity), under-
lying medical conditions, presenting symptoms and signs, labo-
ratory values within 48 hours of admission, severe complica-
tions,andclinicaloutcomesandinterventionsbetweenpatients
in the registry diagnosed with MIS-C vs COVID-19. We se-
lectedcommonlytestedlaboratoryvalueswithvaluesonatleast
70% of patients (absolute lymphocyte count, absolute neutro-
philcount,neutrophiltolymphocyteratio[NLR],plateletcount,
hemoglobin level, alanine aminotransferase level, C-reactive
protein [CRP] level, and albumin level) or of relevance to MIS-C
(B-type natriuretic peptide [BNP] or N-terminal–proBNP) based
on past studies.10,14 Initial measurements of inflammatory or
hematologic biomarkers (NLR, CRP, and platelets) within the
first 2 days of admission were used. Laboratory cutoffs were
dichotomized based on the cutoff for thrombocytopenia or
around median baseline values in the full cohort (CRP and
NLR).24 We were unable to conduct a planned comparison of
RT-PCR and antibody testing differences between patients with
MIS-C and COVID-19 because few patients (12%) with acute
COVID-19 received antibody testing. Based on emerging evi-
dence from small case series and 1 latent class analysis,8,11,14 we
evaluated differences in 5 mutually exclusive severe organ in-
volvement subcategories of MIS-C and COVID-19: (1) cardiores-
piratory involvement, (2) cardiovascular without respiratory in-
volvement, (3) respiratory without cardiovascular involvement,
(4) mucocutaneous without cardiovascular or respiratory in-
volvement,and(5)otherorgansysteminvolvementwithoutcar-
diovascular, respiratory, or mucocutaneous involvement. We
compared invasive mechanical ventilator support and vasoac-
tive agent scores by day of hospitalization among patients with
MIS-C vs COVID-19. Among patients with MIS-C, we evaluated
theresolutionofcardiacdysfunctionovertimeamongthosewith
reduced LVEF or coronary artery aneurysms.
Statistical Analysis
For univariate comparisons between patients with MIS-C and
COVID-19, we used the χ2 test for categorical variables, Fisher
exact test for variables with small sample sizes (n <5), or Kruskal-
Wallis test for continuous variables. We used bivariable analy-
sis to evaluate differences in the 5 mutually exclusive severe
organ involvement subcategories of MIS-C and COVID-19.
We compared the association of selected baseline patient
demographic and clinical characteristics with the diagnosis of
MIS-C vs COVID-19 by fitting a Poisson regression with robust
variance estimates to generate risk ratios.25 Patient baseline
demographic and clinical characteristics were selected based
on whether there were meaningful differences in bivariable
analyses between MIS-C and COVID-19 diagnoses.5,11,14 To
evaluate whether clinicians were ascribing a diagnosis of MIS-C
vs COVID-19 based on clinical syndrome or laboratory fea-
tures, we also evaluated the association between described se-
vere organ involvement subcategories and laboratory mark-
ers of inflammation or hematologic dysfunction with less than
30% overall missingness within the first 2 days of admission.14
Models were adjusted for age (0-5 years, 6-12 years, and 13-20
years), race/ethnicity (non-Hispanic White, non-Hispanic Black,
other non-Hispanic, or Hispanic of any race), sex, US Census
region to account for between-region differences, and pres-
ence of 1 or more vs no underlying conditions. Model conver-
gence was evaluated using the GENMOD function in SAS. Risk
differences were calculated using the adjrr command in Stata.26
We assessed cardiac outcomes using Kaplan-Meier esti-
mates up to 90 days after hospital admission (when available)
among patients with MIS-C and cardiac involvement. For pa-
tients with MIS-C and a diagnosis of coronary artery aneurysm
or reduced LVEF, resolution was plotted using Kaplan-Meier
curves. Patients were censored when resolution was docu-
mented or, if resolution was not confirmed, by date of last echo-
cardiographic evaluation. For patients with MIS-C and COVID-
19, the percentages receiving invasive mechanical ventilation
and vasoactive agents were plotted graphically throughout the
hospitalization. Missing data were not imputed for common
laboratory markers of interest. Statistical significance was des-
ignated as P < .05 (2-sided). Because of the potential for type I
error due to multiple comparisons, findings for analyses should
be interpreted as exploratory. Analyses were conducted in R ver-
sion 3.6.1 (R Project for Statistical Computing), Stata version 16.0
(StataCorp), and SAS version 9.4 (SAS Institute).
Results
Demographics and Clinical Characteristics Among All Patients
From March 15 to October 31, 2020, 1314 hospitalized chil-
dren and adolescents younger than 21 years of age with
Box 1. Centers for Disease Control and Prevention
Case-Definition for MIS-Ca
• Age <21 y
• Fever 38.0 °C for 24 h or report of subjective fever lasting 24 h
• Laboratory evidence of inflammationb
• Evidence of clinically severe illness requiring hospitalization with
multisystem (2) organ involvement (cardiac, kidney, respiratory,
hematologic, gastrointestinal, dermatologic, or neurological)
• No alternative plausible diagnoses
• Positive for current or recent SARS-CoV-2 infection by RT-PCR,
antibody, or antigen test; or exposure to a suspected or confirmed
COVID-19 case within the 4 wk prior to the onset of symptomsc
Abbreviations: COVID-19, coronavirus disease 2019; MIS-C, multisystem
inflammatory syndrome in children; RT-PCR, reverse transcriptase–polymerase
chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
a Must meet all criteria after adjudication by site and coordinating center
principal investigators.
b Including, but not limited to, 1 or more of the following: an elevated
C-reactive protein, erythrocyte sedimentation rate, fibrinogen,
procalcitonin, D-dimer, ferritin, lactate dehydrogenase, interleukin 6,
elevated neutrophils, reduced lymphocytes, and low albumin level.
c Patients without a positive SARS-CoV-2 test result were excluded after May
31, 2020, when site RT-PCR and antibody testing was more available.
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COVID-19–related illness were reported from 66 hospitals in
31 states (eTable 3 in the Supplement). Of 775 children and ado-
lescents (59%) without a diagnosis of MIS-C, 198 were ex-
cluded because they did not meet prespecified criteria for se-
vere COVID-19 (Figure 1). Of the 1116 cases included in the final
analysis, 539 (48%) were classified as MIS-C and 577 (52%) as
acute COVID-19 (Figure 1). In patients with MIS-C, 52% had a
positive SARS-CoV-2 RT-PCR test result, 45% were SARS-
CoV-2 antibody positive only, 31% were positive for both, and
19% did not have an antibody test performed (eTable 4 in the
Supplement). By definition, results of all patients with
COVID-19 were SARS-CoV-2 RT-PCR positive but only 12% re-
ceived antibody testing (60% [43/72] positive).
Compared with patients with COVID-19, those with MIS-C
were younger, more likely to be non-Hispanic Black, and less
likely to have 1 or more chronic medical conditions (Table 1).
Presenting symptoms and signs were similar among patients
with MIS-C and COVID-19 with the exception of mucocutane-
ous findings (66.8% [95% CI, 63%-71%] vs 10.2% [95% CI, 8%-
13%]; P < .001), which were uncommon in patients with
COVID-19 and prevalent in those with MIS-C (Table 1). IVIG was
administered to 77% of patients with MIS-C (78% of whom also
received systemic steroids; 9% received steroids alone) com-
pared with 4% of patients with COVID-19 (Table 2). Ten pa-
tients (1.9%) with MIS-C vs 8 (1.4%) with COVID-19 died dur-
ing hospitalization (described in eTable 5 in the Supplement).
Inflammation and Severe Organ System Involvement
Eighty percent of patients with MIS-C and COVID-19 each had
severe respiratory involvement; however, more patients with
MIS-C had cardiac involvement (66.7% [95% CI, 63%-71%])
compared with patients with COVID-19 (11.8% [95% CI,
Box 2. Case-Definition for Severe Acute COVID-19a,b
• Admitted to the hospital with symptoms suspected to be related to
COVID-19
• Evidence of infection with SARS-CoV-2 based on a positive RT-PCR
test result during current illness
• Severe organ system involvement including at least 1 of the following:
Respiratory
Receipt of mechanical ventilation or any type of supplemental
oxygen (or increased support for patients receiving respiratory
support at baseline)
Severe bronchospasm requiring continuous bronchodilators
Pulmonary infiltrates on chest radiograph
Lower respiratory infection
Pleural effusion
Pneumothorax or other signs of barotrauma
Pulmonary hemorrhage
Chest tube or drainage required
Cardiovascular
Cardiac dysrhythmia or arrhythmia
Ejection fraction <55%
Pulmonary edema due to left heart failure
Coronary artery aneurysm (LAD or RCA z score 2.5)
B-type natriuretic peptide 1000 pg/mL2
Elevated troponin-based on the upper limit of normal for the site
laboratory
Receipt of vasopressor or vasoactive support
Receipt of cardiopulmonary resuscitation or ECMO support
Kidney
Receipt of dialysis (for patients without chronic kidney failure)
Acute kidney injuryc (in patients without prior kidney disease)
Neurologic
Stroke or acute intracranial hemorrhage
Seizures
Coma
Encephalitis, aseptic meningitis, or demyelinating disorder (eg, acute
disseminated encephalomyelitis) diagnosed by a neurologist






Gallbladder hydrops or edema
Other complications as determined by site clinicians included
ileitis, colitis, or mesenteric adenitis
Hematologic
Absolute lymphocyte count <1 ×103 cells/μL
Absolute neutrophil count <0.5 ×103 cells/μL excluding chemo-
therapy patients3
Severe anemiad





Ischemia of an extremity
Other complications as determined by site clinicians included
hemolytic uremic syndrome, anemia requiring transfusion,
and pancytopenia
Abbreviations: COVID-19, coronavirus disease 2019; ECMO, extracorporeal
membrane oxygenation; LAD, left anterior descending; MIS-C, multisystem
inflammatory syndrome in children; RCA, right coronary artery; RT-PCR,
reverse transcriptase–polymerase chain reaction; SARS-CoV-2, severe acute
respiratory syndrome coronavirus 2.
a Must meet all criteria. On August 13, 2020, the registry was restricted to
patients admitted to the intensive care unit or high-acuity stepdown unit for
patients without MIS-C.
b Case definition was created by clinical consensus among the Overcoming
COVID-19 steering committee principal investigators.
c Acute kidney injury was defined as a creatinine level equal to or above the
following values by age18: less than 4 weeks: 1.59 mg/dL; 4 weeks to less than
1 year: 0.62 mg/dL; 1 to 10 years: 1.13 mg/dL; and 11 years: >1.59 mg/dL.
d Severe anemia was defined as hemoglobin level less than 7 g/dL among
children younger than 59 months of age, otherwise hemoglobin level less
than 8 g/dL.19
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9%-15%]) (Table 2). On laboratory testing within 48 hours of
admission, patients with MIS-C had a higher median NLR (6.4
vs 2.7, P < .001) and CRP level (152 mg/L vs 33 mg/L, P < .001)
and more thrombocytopenia (platelets <150 ×103 cells/μL) than
patients with COVID-19 (41% vs 17%, P < .001).
Factors Distinguishing MIS-C vs Severe Acute COVID-19
in Multivariable Model
Compared with patients with COVID-19, patients diagnosed
with MIS-C were more likely to be 6 to 12 years old (40.8% vs
19.4%; absolute risk difference [RD], 21.4% [95% CI, 16.1%-
26.7%]), be non-Hispanic Black (32.3% vs 21.5%; RD, 10.8%
[95% CI, 5.6%-16.0%]), and have no underlying conditions
(69.0% vs 37.9%; RD, 31.1% [95% CI, 25.5%-36.6%]) (Figure 2A).
Adjusting for other covariates, risk of MIS-C diagnosis was
higher for patients aged 6 to 12 years vs 0 to 5 years (aRR, 1.51
[95% CI, 1.33-1.72]) and patients who were non-Hispanic Black
vs White (aRR, 1.43 [95% CI, 1.17-1.76]). Certain clinical syn-
dromes and laboratory features were also associated with di-
agnosis of MIS-C vs COVID-19 (Figure 2B). Compared with
COVID-19, patients with MIS-C were more likely to have car-
diorespiratory involvement (56.0% vs 8.8%; RD, 47.2% [95%
CI, 42.4%-52.0%]), cardiovascular without respiratory involve-
ment (10.6% vs 2.9%; RD, 7.7% [95% CI, 4.7%-10.6%]), and mu-
cocutaneous without cardiorespiratory involvement (7.1% vs
2.3%; RD, 4.8% [95% CI, 2.3%-7.3%]). Compared with pa-
tients with respiratory involvement alone, MIS-C diagnosis was
more likely in patients with cardiorespiratory involvement
(aRR, 2.99 [95% CI, 2.55-3.50]), cardiovascular without respi-
ratory involvement (aRR, 2.49 [95% CI, 2.05-3.02]), and mu-
cocutaneous without cardiorespiratory involvement (aRR, 2.29
[95% CI, 1.84-2.85]).
Additionally, patients with an NLR greater than 5, plate-
let count less than 150 ×103/μL, and CRP level greater than 100
mg/L within 48 hours of admission were more likely to be di-
agnosed with MIS-C. In contrast, patients with COVID-19 were
more likely to have 1 or more underlying conditions; respira-
tory without cardiovascular involvement; or hematologic, neu-
rologic, or gastrointestinal involvement without cardiovascu-
lar, respiratory, or mucocutaneous involvement. The regression
model RDs are shown in eTable 6 in the Supplement. The num-
ber of patients excluded from the regression analyses varied
based on the variables included in the model and ranged from
0 to 340 (depending on the laboratory marker of interest).
RT-PCR and Antibody Status by Clinical Subphenotype
The results of 92% of patients with severe respiratory involve-
ment without cardiovascular involvement and 95% with he-
matologic, neurologic, or gastrointestinal severe involve-
ment without severe respiratory or cardiovascular involvement
were RT-PCR positive. Antibody positivity within these groups
was 21% and 10%, respectively; however, 74% and 86% were
not tested (details in eTable 7 in the Supplement). RT-PCR posi-
tivity was observed in fewer patients with severe cardiovas-
cular involvement (range, 57%-58%) and mucocutaneous in-
volvement without cardiovascular or respiratory involvement
(45%) (details in eTable 7 in the Supplement).
The results from most patients with severe cardiorespira-
tory involvement, severe cardiovascular without respiratory
involvement, and mucocutaneous without cardiorespiratory
involvement were antibody positive (69%, 74%, and 61%, re-
spectively, with 74%, 77%, and 71% tested). Comparing only
patients with MIS-C by SARS-CoV-2 status, RT-PCR–positive
and –negative patients with positive SARS-CoV-2 antibody re-
sults had similar demographic and clinical characteristics and
outcomes (eTable 8 in the Supplement).
Respiratory Support and Vasoactive Agent Utilization
For patients who had data available on respiratory support, 9%
of patients with MIS-C vs 10% with COVID-19 received inva-
sive mechanical ventilation on admission day 1 (Figure 3A). The
percentage of patients requiring ventilator support peaked on
day 4 for patients with MIS-C (17%) and day 3 for those with
COVID-19 (13%). Fifty patients (9%) with COVID-19, compared
Figure 1. Eligibility Flowchart of Hospitalized Patients With COVID-19–Related Illness, March 15-October 31, 2020
47 Non–MIS-C patients excluded
40 SARS-CoV-2 RT-PCR negative
7 Unknown test status
198 Did not meet the definition
for severe COVID-19
1361 Patients aged <21 y with presumptive hospitalized
MIS-C or COVID-19 submitted to registry based on 
site determination and adjudicated at coordinating
center to meet criteria for registrya,b
775 RT-PCR positive and did not meet
MIS-C criteria by site or coordinating
center adjudication
577 Adjudicated to meet criteria for severe
acute COVID-19 and included in the
primary analysis
539 Adjudicated to meet criteria for
MIS-C and included in the primary
analysis
COVID-19 indicates coronavirus
disease 2019; RT-PCR, reverse
transcriptase–polymerase chain
reaction; SARS-CoV-2, severe acute
respiratory syndrome coronavirus 2;
and MIS-C, multisystem inflammatory
syndrome in children.
a Registry data was based on voluntary
case reporting by participating
sentinel surveillance sites.
b Criteria for registry: meet case
definition for MIS-C (Box 1) or
evidence of infection with
SARS-CoV-2 based on a positive
RT-PCR test result during current
illness with clinical suspicion for
acute COVID-19.
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Table 1. Baseline Characteristics of Patients With MIS-C and Severe Acute COVID-19 and Initial Laboratory Values Within 48 Hours of Admissiona,b,c
Characteristic
Study cohort from the Overcoming COVID-19 registry (N = 1116)
MIS-C (n = 539) Severe acute COVID-19 (n = 577)
Age, median (IQR), y 8.9 (4.7-13.2) 11.7 (1.2-16.6)
Sex, No. (%)
Male 312 (57.7) 307 (53.2)
Female 227 (42.1) 270 (47.8)
Race/ethnicity, No. (%)d
No. 421 529
White, non-Hispanic (n = 174) 66 (13.3) 108 (19.0)
Black, non-Hispanic (n = 310) 181 (34.7) 129 (22.7)
Hispanic or Latino (n = 455) 193 (35.9) 262 (45.5)
Other, non-Hispanic (n = 67) 27 (5.5) 40 (7.1)
Underlying medical conditions, No. (%)
At least 1 underlying conditione 167 (30.9) 358 (62.1)
Obesityf 176 (36.2) 176 (41.8)
Respiratory 72 (13.4) 151 (26.2)
Otherg 52 (9.6) 223 (38.6)
Neurological/neuromuscular 30 (5.6) 104 (18.0)
Cardiovascular 17 (3.2) 57 (9.8)
Clinical presentation on hospital admission
Duration of symptoms/signs prehospitalization, d
No. 503 516
Median (IQR) 4.0 (3.0-6.0) 3.0 (1.0-5.0)
Organ systems involved, median (IQR)h 4.0 (3.0-5.0) 2.0 (1.0-3.0)
Symptoms and signs on presentation, No. (%)i
Constitutional 536 (99.4) 472 (81.8)
Gastrointestinal 486 (90.2) 332 (57.5)
Mucocutaneous 360 (66.8) 59 (10.2)
Lower respiratory 232 (43.0) 359 (62.2)
Upper respiratory 184 (34.1) 185 (32.1)
Neurologic 218 (40.4) 186 (32.2)
Initial laboratory value within 48 h of admissionj
Absolute lymphocyte count, ×103 cells/μL
(normal range, 1-5.6 ×103 cells/μL,
depending on age and sex)
No. 505 459
Median (IQR) 1.3 (0.7-3.1) 1.75 (1.0-3.5)
Absolute neutrophil count, ×103 cells /μL
(normal range, 2.2-9.4 ×103 cells/μL,
depending on age and sex)
No. 515 481
Median (IQR) 8.0 (5.0-13.0) 5.2 (2.8-9.2)
Neutrophil to lymphocyte ratio (normal range
not established)
No. 515 464
Median (IQR) 6.4 (3.4-12.4) 2.7 (1.1-6.5)
Platelet count <150 ×103 cells/μL (n = 1009) 212 (41) 84 (17)
Hemoglobin level, g/dL (normal range, 10.2-11.4 g/dL,
depending on age and sex)
No. 483 449
Median (IQR) 11.3 (10.2-12.3) 12.3 (10.7-14.0)
Alanine aminotransferase level, U/L
(normal range, 3-54 U/L,
depending on age and sex)
No. 458 335
Median (IQR) 34.5 (21.0-67.9) 30.0 (18.0-55.0)
(continued)
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with 244 (45%) with MIS-C, received vasoactive agents
(Table 2); the MIS-C and COVID-19 groups showed similar de-
creases in the percentage receiving vasoactive agent support
over time (Figure 3B).
Cardiac Complications
In patients with MIS-C, among 503 (93.3%) in whom LVEF could
be evaluated on 1 or more echocardiograms, 331 (65.8%) had
preserved LVEF throughout the illness. Of the 172 patients
(34.2%) with MIS-C and depressed LVEF, the lowest EF was
mildly depressed in 95 (55.2%), moderately depressed in 39
(22.7%), and severely depressed in 38 (22.1%). By Kaplan-
Meier analysis with censoring at the last echocardiogram, 91.0%
(95% CI, 86.0%-94.7%) had a normal LVEF by 30 days
(Figure 4A), and, based on a small number of patients with
available follow-up, 99.4% (95% CI, 96.9%-99.9%) had nor-
mal LVEF by 90 days. The 1 patient without normalization
documented within 90 days who had further echocardio-
graphic analysis had a normal LVEF at 142 days. The severity
of initial systolic dysfunction did not affect the likelihood of
EF recovery (log-rank test, P = .88). Coronary arteries were
evaluated in 424 of 504 patients (84.1%) with MIS-C who had
echocardiograms (eTable 9 in the Supplement). Among these,
57 patients (13.4%) had coronary aneurysms, of which 53
(93.0%) were mild, 4 (7.0%) were moderate, and none were
large/giant. Aneurysms regressed to normal internal lumen di-
ameter (z score <2.5) in 79.1% (95% CI, 67.1%-89.1%) of pa-
tients by 30 days (Figure 4B) and, based on small numbers,
100% by 90 days. Fewer patients with COVID-19 (111/578,
19.2%) underwent echocardiographic assessment; depressed
EF (6/111, 5.4%) and coronary aneurysms (1/111, 0.9%) were in-
frequent in those evaluated.
Discussion
In this case series comparing children and adolescents with
MIS-C vs those with severe COVID-19, MIS-C was distin-
guished by certain demographic features and clinical pres-
entations including being aged 6 to 12 years, being of
non-Hispanic Black race, having severe cardiovascular or mu-
cocutaneous involvement, and having more extreme inflam-
mation. Patients from both groups commonly presented with
a variety of constitutional, gastrointestinal, and upper or lower
respiratory signs or symptoms on admission. Both groups
often required intensive care unit support, more commonly
in the MIS-C group. Although the results for most patients
with MIS-C were SARS-CoV-2 antibody positive, most
patients with COVID-19 were not antibody tested. Most
severe cardiovascular involvement from MIS-C, including left
ventricular dysfunction and coronary artery aneurysms,
resolved within 30 days.
Previous studies have reported that a large proportion
of pediatric patients with COVID-19–related disease were of
Black race or Hispanic ethnicity, but these studies were lim-
ited in their ability to establish an association between race/
ethnicity as a potential risk factor for MIS-C.8,14,27 This case se-
ries found that non-Hispanic Black children and adolescents
were more likely than non-Hispanic White patients to have
MIS-C than COVID-19, after adjusting for age, sex, geographic
Table 1. Baseline Characteristics of Patients With MIS-C and Severe Acute COVID-19 and Initial Laboratory Values Within 48 Hours of Admissiona,b,c
(continued)
Characteristic
Study cohort from the Overcoming COVID-19 registry (N = 1116)
MIS-C (n = 539) Severe acute COVID-19 (n = 577)
C-reactive protein level, mg/L (normal range ≤5 mg/L)
No. 491 285
Median (IQR) 152.0 (69.4-231.0) 33.0 (10.1-90.0)
Albumin level ≤3 g/dL (n = 793) 146 (32.0) 43 (12.8)
Abbreviations: COVID-19, coronavirus disease 2019; IQR, interquartile range;
MIS-C, multisystem inflammatory syndrome in children; RT-PCR, reverse
transcriptase–polymerase chain reaction.
SI conversion factor: To convert to alanine aminotransferase, multiply by 0.0167.
a MIS-C is defined in Box 1.
b Severe acute COVID-19 was defined as severe complications involving 1 organ
system or more and evidence of infection with severe acute respiratory
syndrome coronavirus 2 based on having a positive RT-PCR test result (Box 2).
Complications categorized as severe are listed in Box 2 by organ system.
c Included children and adolescents younger than 21 years of age from 66
hospitals in 31 states from March 15 to October 31, 2020.
d Race and ethnicity were recorded from hospital medical records as reported by
the site clinicians or in the medical record; categories are not mutually exclusive.
e Underlying conditions excluded body mass index (BMI, calculated as weight in
kilograms divided by height in meters squared)–estimated obesity (defined as
BMI >95th percentile for age and sex based on national reference standards).
f A patient was considered to have obesity by either clinician-diagnosed obesity
or BMI-based obesity and is only calculated in children aged 2 years or older;
thus, the denominator is 893.
g Other category included oncologic, immunosuppressive, rheumatologic,
autoimmune, hematologic, kidney, urologic, gastrointestinal, hepatic,
endocrine, and metabolic conditions.
h Organ systems involved includes cardiovascular, respiratory, kidney,
neurologic, gastrointestinal, hematologic, mucocutaneous, and
musculoskeletal.
i Presenting signs and symptoms were recorded from hospital medical records
and included constitutional symptoms (fever, fatigue, muscle aches/joint
pain), gastrointestinal symptoms (nausea/refusal to eat, vomiting, abdominal
pain, diarrhea), upper respiratory (rhinorrhea, congestion, and sore throat),
lower respiratory (cough, shortness of breath, chest pain, wheezing, lower
chest wall indrawing), mucocutaneous findings (rash, inflammation of the oral
mucosa, conjunctivitis, and extremity findings, including erythema or edema
of the hands or feet, or periungual peeling), hematological signs (abnormal cell
counts or clotting function), and neurologic symptoms (headache, altered
mental status/confusion).
j Clinically significant laboratory values that were commonly tested are
presented here.
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region, and underlying conditions, whereas Hispanic pa-
tients did not appear to be at a higher risk for MIS-C than
COVID-19.14 In Kawasaki disease, Black race is a risk factor for
nonresponse to IVIG treatment and increased frequency of
coronary abnormalities.28,29
Similar to prior single-center studies, LVEF was found to
normalize in most patients with MIS-C within 1 to 2 weeks.30-32
Patients with severely depressed EF had a similar likelihood
and temporal trajectory of recovery to those with mild dys-
function. The recovery of LVEF within a few weeks of diagno-
sis in most patients with MIS-C suggests that LV dysfunction
likely results from severe systemic inflammation and acute
stress more often than from ischemia or direct virus-
mediated myocardial damage. However, Matsubara et al30
demonstrated persistent abnormalities in strain and diastolic
function in patients with MIS-C and normal EF. These data, to-
gether with literature in adult patients with COVID-19,33 sug-
gest that subclinical myocardial injury may persist even when



















Comparison of baseline demographic and clinical characteristicsaA
178 (33.0) 211 (36.6) –3.5 (–9.1 to 2.0)0-5 1 [Reference]
<.001220 (40.8) 112 (19.4) 21.4 (16.1 to 26.7)6-12 1.51 (1.33 to 1.72)
.89141 (26.2) 254 (44.0) –17.9 (–23.4 to –12.4)13-20 0.99 (0.84 to 1.17)
Race/ethnicityd
63 (11.7) 106 (18.4) –6.7 (–10.8 to –2.5)White, non-Hispanic 1 [Reference]
<.001174 (32.3) 124 (21.5) 10.8 (5.6 to 16.0)Black, non-Hispanic 1.43 (1.17 to 1.76)
Sex
312 (57.9) 307 (53.2) 4.7 (–1.1 to 10.5)Male 1 [Reference]
.08227 (42.1) 270 (46.8) –4.7 (–10.5 to 1.1)Female 0.90 (0.81 to 1.01)
≥1 Underlying medical conditions
372 (69.0) 219 (37.9) 31.1 (25.5 to 36.6)No 1 [Reference]
<.001167 (31.0) 358 (62.1) –31.1 (–36.6 to –25.5)Yes 0.52 (0.45 to 0.60)




















Comparison of clinical phenotypes and laboratory valuesaB
130/539 (24.1) 408/577 (70.7) –46.6 (–51.8 to –41.4)Respiratory without cardiovascular 1 [Reference]
<.001302/539 (56.0) 51/577 (8.8) 47.2 (42.4 to 52.0)Cardiorespiratory 2.99 (2.55 to 3.50)
<.00157/539 (10.6) 17/577 (2.9) 7.7 (4.7 to 10.6)Cardiovascular without respiratory 2.49 (2.05 to 3.02)
Laboratory value within first 48 h
321/515 (62.3) 154/464 (33.2) 29.1 (23.2 to 35.1)Neutrophil to lymphocyte ratio >5 1.59 (1.40 to 1.80) <.001
<.001212/523 (40.5) 84/486 (17.3) 23.2 (17.9 to 28.6)Platelets <150 × 103/μL 1.58 (1.43 to 1.75)
<.001325/491 (66.2) 67/285 (23.5) 42.7 (36.2 to 49.1)C-reactive protein level >100 mg/L 1.70 (1.51 to 1.92)
<.00138/539 (7.1) 13/577 (2.3) 4.8 (2.3 to 7.3)Mucocutaneous without respiratory
or cardiovascular
2.29 (1.84 to 2.85)
.00212/539 (2.2) 88/577 (15.3) –13.1 (–16.2 to –9.8)Other without respiratory,
cardiovascular, or mucocutaneous
0.43 (0.25 to 0.74)
COVID-19 indicates coronavirus disease 2019 and MIS-C, multisystem
inflammatory syndrome in children.
a Included children and adolescents younger than 21 years of age from 66
hospitals in 31 states from March 15 to October 31, 2020.
b Absolute row differences in characteristic between patients with MIS-C and
COVID-19 with exact confidence intervals; a positive value indicates that the
characteristic was more common in children and adolescents diagnosed with
MIS-C.
c The primary outcome is diagnosis of MIS-C vs COVID-19. A risk ratio greater
than 1 represents a higher relative risk of MIS-C in the respective row relative
to the referent group within that category. Associations were adjusted for age
group (0-5 years, 6-12 years, 13-20 years), race/ethnicity (non-Hispanic White,
non-Hispanic Black, Hispanic of any race, other non-Hispanic), sex, 1 or more
vs no underlying medical conditions, and US Census region (Northeast, South,
Midwest, West).
d Other non-Hispanic race/ethnicity, which included patients documented as
having other, unknown, or mixed race, not shown in the table.
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traditional measures of LV systolic function are normal. To un-
derstand the longer-term implications for myocardial health,
including risk for myocardial fibrosis and diastolic dysfunc-
tion, it is critical to have comprehensive assessment of LV sys-
tolic and diastolic function in a large, multicenter cohort fol-
lowed up longitudinally with centralized review of cardiac
imaging. Cardiac magnetic resonance imaging and the rare en-
domyocardial biopsy or postmortem specimen may further
help to clarify the underlying pathology and mechanisms of
myocardial involvement in MIS-C.
Coronary artery aneurysms were generally small in size and
regressed to normal internal lumen diameter within several
weeks in a population that was often treated with IVIG, an ef-
fective therapy for reduction of prevalence of aneurysms in
Kawasaki disease.22 The pathophysiology of coronary enlarge-
ment in MIS-C has not been elucidated. However, the mild se-
verity and rapid resolution may suggest that coronary enlarge-
ment in MIS-C more often results from vasodilation in the
setting of a highly proinflammatory milieu,34 rather than from
destruction of the arterial wall by inflammatory cells.35 Coro-
nary imaging results were abstracted from reports of echocar-
diograms performed at varying times after hospital dis-
charge, using inconsistent z score calculators, and of uncertain
imaging quality. Future studies using standardized protocols
and core laboratory interpretation will build on the results of
this study and others.36




















































































































































































































































A, Graph shows mechanical ventilator
support and death among patients
with MIS-C (n = 529 with respiratory
support data available) and patients
with severe acute COVID-19 (n = 563
with respiratory support data
available). B, Graph shows
vasopressor support and death
among patients with MIS-C (n = 528
with vasopressor support data
available) and patients with severe
acute COVID-19 (n = 565 with
vasopressor support data available).
Percentages receiving mechanical
ventilator or vasopressor support by
day of admission use the full
denominators specified at day 1 (the
initial day of hospitalization). Some
patients had missing information on
mechanical ventilator or vasopressor
use and are excluded. Tables below
the x-axis present the number of
patients with MIS-C and COVID-19
still hospitalized by admission day,
the number on mechanical
ventilation or receiving vasopressor
support, and the cumulative deaths
during index hospitalization.
Cardiovascular pediatric Severe
Organ Failure Assessment (pSOFA)
scores range from 0 to 4 and were
documented daily through 7 days,
twice weekly through day 22, then at
day 28. Details of pSOFA score
criteria are included in eTable 2 in the
Supplement. Scores of 2 to 4,
indicating vasopressor use, are
presented in the figure. COVID-19
indicates coronavirus disease 2019;
MIS-C, multisystem inflammatory
syndrome in children.
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Most patients classified as having MIS-C and COVID-19 ex-
perienced severe respiratory involvement and it is possible that
some patients may have had COVID-19 with cardiovascular in-
volvement, as has been described in adult patients, rather than
MIS-C.37 Current criteria for MIS-C may also capture a spec-
trum of hyperinflammation and cardiovascular involvement
occurring acutely and during the postinfectious phase. Mis-
classification of these patients might impede optimal treat-
ment if the pathogenesis differs between MIS-C and COVID-
19; however, it is possible that anti-inflammatory agents like
steroids could be beneficial for both.38,39 Although longer-
term follow-up is needed to assess outcomes and sequelae,
most children with MIS-C with severe cardiac manifestations
experienced clinical recovery within 30 days.
Limitations
This study has several limitations. First, data collection through
in-depth abstraction of routine clinical documentation is sub-
ject to incomplete reporting. Research personnel at each site
abstracted data and were part of a large research network with
extensive data collection experience and intensive data clari-
fication procedures. Second, missing data were not imputed
and missingness might be nonrandom. Third, participating hos-
pitals may not be generalizable and likely overrepresented pa-
tients seeking care at tertiary care centers. Fourth, although
93% of patients with MIS-C had echocardiograms, most pa-
tients with severe COVID-19 did not have detailed cardiac as-
sessments. Among patients with COVID-19, only 19% had echo-
cardiograms, and although LV dysfunction and coronary
aneurysms were rare, they could have been underappreci-
ated. Fifth, the efficacies of different immunomodulatory regi-
mens on recovery of LV function in the current study were not
examined.40 Sixth, because MIS-C is thought to be delayed in
onset after SARS-CoV-2 infection,5,38 its distinction from acute
COVID-19 could be improved by elucidating the temporal pro-
gression from viral exposure to disease onset.
Conclusions
This case series of patients with MIS-C and with COVID-19 iden-
tified patterns of clinical presentation and organ system in-
volvement. These patterns may help differentiate between
MIS-C and COVID-19.
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Median, 6 (IQR, 3-18) days of observationLog-rank P = .88
Median, 4 (IQR, 3-8) days of observation
A. Graph shows resolution of decreased left ventricular ejection fraction (EF) on
echocardiogram with mild (EF, 45% to <55%), moderate (EF, 35% to <45%),
and severe (EF<35%) impairment with days to normalization (EF 55%).
B, Graph shows resolution of coronary artery aneurysms defined as z score
2.5 for left anterior descending or right coronary artery.
Patients were evaluated from the day of first echocardiographic evaluation and
censored on the day when repeat echocardiograph showed recovery or on the
day of their last repeat echocardiogram if they had not recovered through
40 days. IQR indicates interquartile range and MIS-C, multisystem inflammatory
syndrome in children.
a Kaplan-Meier curves shown up to 40 days from admission given early resolution
of cardiac dysfunction in most patients with few uncensored by 40 days. Five
patients were censored before documented resolution of reduced left ventricular
EF at a median time of 2 days (range, 0-8 days); all other patients had resolution
documented by 142 days. Nine patients were censored before documented
resolution of coronary artery aneurysms at a median time of 4 days (range, 0-30
days); all other patients had resolution documented by 76 days.
Research Original Investigation Characteristics and Outcomes of US Children and Adolescents With MIS-C Compared With Severe Acute COVID-19
E12 JAMA Published online February 24, 2021 (Reprinted) jama.com
© 2021 American Medical Association. All rights reserved.
Medicine, Department of Pediatrics, University of
Texas Southwestern, Children’s Medical Center
Dallas, Dallas (Bowens, Maamari); Division of
Critical Care Medicine, Department of Pediatrics,
Nationwide Children’s Hospital, Columbus, Ohio
(Hall); Department of Anesthesiology and Critical
Care Medicine, Division of Pediatric Anesthesiology
& Critical Care Medicine, Johns Hopkins School of
Medicine, Baltimore, Maryland (Riggs); Division of
Critical Care, Department of Pediatrics, Yale
University School of Medicine, New Haven,
Connecticut (Giuliano); Pediatric Critical Care
Division, Maria Fareri Children’s Hospital at
Westchester Medical Center and New York Medical
College, Valhalla (Singh); Department of Pediatrics,
Division of Pediatric Critical Care, Bristol-Myers
Squibb Children’s Hospital, Robert Wood Johnson
Medical School, Rutgers University, New Brunswick,
New Jersey (Li); Division of Pediatric Critical Care
Medicine, Department of Pediatrics, University of
Alabama at Birmingham (Kong); Division of
Pediatric Infectious Disease, Department of
Pediatrics, Children’s Mercy Kansas City, Kansas
City, Missouri (Schuster); Division of Pediatric
Critical Care Medicine, Department of Pediatrics,
University of Miami Miller School of Medicine,
Miami, Florida (McLaughlin); Department of
Pediatrics, University of North Carolina at Chapel
Hill Children’s Hospital (Schwartz, Walker); Section
of Critical Care Medicine, Department of Pediatrics,
Baylor College of Medicine, Houston, Texas (Loftis);
Division of Infectious Diseases, Department of
Pediatrics, Department of Microbiology, University
of Mississippi Medical Center, Jackson (Hobbs);
Division of Pediatric Infectious Diseases,
Department of Pediatrics, Vanderbilt University
Medical Center, Nashville, Tennessee (Halasa);
Division of Pediatric Critical Care, Department of
Pediatrics, SUNY Downstate Health Sciences
University, Brooklyn, New York (Doymaz); Division
of Pediatric Critical Care, Miller Children’s and
Women’s Hospital of Long Beach, Long Beach,
California (Babbitt); Division of Pediatric Critical
Care, University of Minnesota Masonic Children’s
Hospital, Minneapolis (Hume); Division of Pediatric
Critical Care, Department of Pediatrics, Saint
Barnabas Medical Center, Livingston, New Jersey
(Gertz); Section of Pediatric Critical Care,
Department of Pediatrics, Arkansas Children’s
Hospital, Little Rock (Irby); Division of Hospital
Medicine, Department of Pediatrics, Hackensack
University Medical Center, Hackensack, New Jersey
(Clouser); Division of Critical Care Medicine, UCSF
Benioff Children’s Hospital Oakland, Oakland,
California (Cvijanovich); Division of Cardiology,
Department of Pediatrics, Louisiana State
University Health Sciences Center and Children’s
Hospital of New Orleans, New Orleans (Bradford);
Division of Pediatric Critical Care Medicine,
Department of Pediatrics, University of
Washington, Seattle (Smith); Division of Pediatric
Critical Care Medicine, Department of Pediatrics,
Central Michigan University, Detroit (Heidemann);
Pediatric Critical Care Medicine, Department of
Pediatrics, Icahn School of Medicine at the Mount
Sinai Kravis Children’s Hospital, New York, New
York (Zackai); Division of Pediatric Critical Care,
Stead Family Department of Pediatrics, University
of Iowa Carver College of Medicine, Iowa City
(Wellnitz); Division of Critical Care Medicine,
Department of Pediatrics, Akron Children’s
Hospital, Akron, Ohio (Nofziger); Department of
Pediatrics, Division of Critical Care, Rutgers Robert
Wood Johnson Medical School, New Brunswick,
New Jersey (Horwitz); Division of Pediatric Critical
Care Medicine, MassGeneral Hospital for Children,
Harvard Medical School, Boston, Massachusetts
(Carroll); Division of Pediatric Critical Care
Medicine, Department of Pediatrics, Indiana
University School of Medicine, Riley Hospital for
Children, Indianapolis (Rowan); Division of Critical
Care Medicine, Department of Pediatrics, Emory
University School of Medicine, Children’s
Healthcare of Atlanta, Atlanta, Georgia (Tarquinio);
Division of Pediatric Critical Care Medicine, Medical
University of South Carolina, Charleston (Mack);
Division of Critical Care, Department of
Anesthesiology and Critical Care, The University of
Pennsylvania Perelman School of Medicine,
Philadelphia (Fitzgerald); Division of Critical Care
Medicine, Department of Pediatrics, Northwestern
University Feinberg School of Medicine, Ann &
Robert H. Lurie Children’s Hospital of Chicago,
Chicago, Illinois (Coates); Division of Immunology,
Boston Children’s Hospital, Department of
Pediatrics, Harvard Medical School, Boston,
Massachusetts (Son); Departments of Anesthesia
and Pediatrics, Harvard Medical School, Boston,
Massachusetts (Randolph).
Author Contributions: Dr Patel had full access to
all of the data in the study and takes responsibility
for the integrity of the data and the accuracy of the
data analysis. Drs Feldstein, Tenforde, and
Friedman contributed equally, as did Drs Patel,
Newburger, and Randolph.
Concept and design: Feldstein, Li, Walker, Hobbs,
Halasa, Doymaz, Horwitz, Patel, Randolph.
Acquisition, analysis, or interpretation of data:
Feldstein, Tenforde, Friedman, Newhams, Rose,
Dapul, Soma, Maddux, Mourani, Bowens, Maamari,
Hall, Riggs, Giuliano, Singh, Li, Kong, Schuster,
McLaughlin, Schwartz, Loftis, Hobbs, Halasa,
Babbitt, Hume, Gertz, Irby, Clouser, Cvijanovich,
Bradford, Smith, Heidemann, Zackai, Wellnitz,
Nofziger, Horwitz, Carroll, Rowan, Tarquinio, Mack,
Fitzgerald, Coates, Jackson, Young, Son, Patel,
Newburger, Randolph.
Drafting of the manuscript: Feldstein, Tenforde,
Friedman, Rose, Doymaz, Jackson, Young, Patel,
Newburger, Randolph.
Critical revision of the manuscript for important
intellectual content: Feldstein, Tenforde, Friedman,
Newhams, Dapul, Soma, Maddux, Mourani,
Bowens, Maamari, Hall, Riggs, Giuliano, Singh, Li,
Kong, Schuster, McLaughlin, Schwartz, Walker,
Loftis, Hobbs, Halasa, Doymaz, Babbitt, Hume,
Gertz, Irby, Clouser, Cvijanovich, Bradford, Smith,
Heidemann, Zackai, Wellnitz, Nofziger, Horwitz,
Carroll, Rowan, Tarquinio, Mack, Fitzgerald, Coates,
Son, Patel, Newburger, Randolph.
Statistical analysis: Feldstein, Tenforde, Rose,
Giuliano, Zackai, Jackson, Young, Randolph.
Obtained funding: Patel, Randolph.
Administrative, technical, or material support:
Feldstein, Tenforde, Newhams, Rose, Dapul,
Maamari, Hall, Riggs, Kong, McLaughlin, Schwartz,
Loftis, Hobbs, Doymaz, Babbitt, Hume, Gertz, Irby,
Bradford, Zackai, Wellnitz, Carroll, Fitzgerald,
Coates, Son, Randolph.
Supervision: Feldstein, Friedman, Newhams, Singh,
Hobbs, Cvijanovich, Horwitz, Carroll, Coates, Patel,
Randolph.
Conflict of Interest Disclosures: Dr Maddux
reported receiving grants from National Institutes
of Health (NIH) (K23HD096018) and Francis Family
Foundation (Parker B. Francis Fellowship) during
the conduct of the study. Dr Mourani reported
receiving grants from the NIH. Dr Hall reported
receiving personal fees from LaJolla
Pharmaceuticals for service on a data safety and
monitoring board outside the submitted work.
Dr Schuster reported receiving grants from Merck
outside the submitted work. Dr Halasa reported
receiving grants from Sanofi, Quindell, and Quidel;
personal fees from Genentech (educational grant);
and hemagglutination inhibition and
microneutralization testing and vaccine donation
from Sanofi outside the submitted work.
Dr Cvijanovich reported receiving grants from
Cincinnati Children’s Hospital Medical Center
outside the submitted work. Dr Rowan reported
receiving grants from the National Heart, Lung, and
Blood Institute (K23HL150244-01A1) outside the
submitted work. Dr Fitzgerald reported receiving
grants from an NIH career development award
outside the submitted work. Dr Newburger
reported serving as chair of events adjudication
committee for a trial on apixaban in children for
Pfizer and Bristol-Myers Squibb, as chair of events
adjudication committee for a trial of Entresto in
children for Novartis, and as a steering committee
member for a trial of endoxaban for Daiichi-Sankyo
outside the submitted work. Dr Randolph reported
receiving royalties from UpToDate and personal
fees from LaJolla Pharma Inc outside the submitted
work. No other disclosures were reported.
Funding/Support: This study was funded by the
Centers for Disease Control and Prevention (CDC)
under a contract to Boston Children’s Hospital.
Role of the Funder/Sponsor: The CDC designed
and conducted the study; collected, managed,
analyzed, and interpreted the data; prepared,
reviewed, and approved the manuscript; and had
a role in the decision to submit the manuscript for
publication and journal choice, and had the right to
veto publication.
Group Information: The Overcoming COVID-19
Investigators are listed in the eAppendix in the
Supplement.
Disclaimer: The findings and conclusions in this
report are those of the authors and do not
necessarily represent the official position of
the CDC.
Additional Contributions: We appreciate and
thank the many research coordinators at the
Overcoming COVID-19 hospitals who assisted in
data collection for this study. We thank the
leadership of the Pediatric Acute Lung Injury and
Sepsis Investigator’s (PALISI) Network for their
ongoing support.
REFERENCES
1. NYC Health. 2020 Health alert 13: pediatric
multi-system inflammatory syndrome potentially
associated with COVID-19. Published May 4, 2020.




2. Riphagen S, Gomez X, Gonzalez-Martinez C,
Wilkinson N, Theocharis P. Hyperinflammatory
shock in children during COVID-19 pandemic. Lancet.
2020;395(10237):1607-1608. doi:10.1016/S0140-
6736(20)31094-1
3. Verdoni L, Mazza A, Gervasoni A, et al.
An outbreak of severe Kawasaki-like disease at the
Italian epicentre of the SARS-CoV-2 epidemic: an
Characteristics and Outcomes of US Children and Adolescents With MIS-C Compared With Severe Acute COVID-19 Original Investigation Research
jama.com (Reprinted) JAMA Published online February 24, 2021 E13
© 2021 American Medical Association. All rights reserved.
observational cohort study. Lancet. 2020;395
(10239):1771-1778. doi:10.1016/S0140-6736(20)
31103-X
4. Centers for Disease Control and Prevention.
Emergency preparedness and response:
HAN00432. Published May 14, 2020. Accessed
December 3, 2020. https://emergency.cdc.gov/
han/2020/han00432.asp
5. Feldstein LR, Rose EB, Horwitz SM, et al;
Overcoming COVID-19 Investigators; CDC COVID-19
Response Team. Multisystem inflammatory
syndrome in US children and adolescents. N Engl J
Med. 2020;383(4):334-346. doi:10.1056/
NEJMoa2021680
6. Dufort EM, Koumans EH, Chow EJ, et al;
New York State and Centers for Disease Control and
Prevention Multisystem Inflammatory Syndrome in
Children Investigation Team. Multisystem
inflammatory syndrome in children in New York
state. N Engl J Med. 2020;383(4):347-358. doi:10.
1056/NEJMoa2021756
7. Sperotto F, Friedman KG, Son MBF, VanderPluym
CJ, Newburger JW, Dionne A. Cardiac
manifestations in SARS-CoV-2-associated
multisystem inflammatory syndrome in children:
a comprehensive review and proposed clinical
approach. Eur J Pediatr. 2021;180(2):307-322. doi:
10.1007/s00431-020-03766-6
8. Swann OV, Holden KA, Turtle L, et al; ISARIC4C
Investigators. Clinical characteristics of children and
young people admitted to hospital with covid-19 in
United Kingdom: prospective multicentre
observational cohort study. BMJ. 2020;370:m3249.
doi:10.1136/bmj.m3249
9. Henderson LA, Canna SW, Friedman KG, et al.
American College of Rheumatology clinical
guidance for pediatric patients with multisystem
inflammatory syndrome in children (MIS-C)
associated with SARS-CoV-2 and hyperinflam-
mation in COVID-19: version 2. Arthritis Rheumatol.
Published online December 5, 2020.
10. Valverde I, Singh Y, Sanchez-de-Toledo J, et al;
AEPC COVID-19 Rapid Response Team. Acute
cardiovascular manifestations in 286 children with
multisystem inflammatory syndrome associated
with COVID-19 infection in Europe. Circulation.
2021;143(1):21-32. doi:10.1161/CIRCULATIONAHA.120.
050065
11. Fernandes DM, Oliveira CR, Guerguis S, et al;
Tri-State Pediatric COVID-19 Research Consortium.
SARS-CoV-2 clinical syndromes and predictors of
disease severity in hospitalized children and youth.
J Pediatr. Published online November 14, 2020. doi:
10.1016/j.jpeds.2020.11.016
12. Lu X, Zhang L, Du H, et al; Chinese Pediatric
Novel Coronavirus Study Team. SARS-CoV-2
infection in children. N Engl J Med. 2020;382(17):
1663-1665. doi:10.1056/NEJMc2005073
13. Götzinger F, Santiago-García B, Noguera-Julián
A, et al; ptbnet COVID-19 Study Group. COVID-19 in
children and adolescents in Europe: a multinational,
multicentre cohort study. Lancet Child Adolesc Health.
2020;4(9):653-661. doi:10.1016/S2352-4642(20)
30177-2
14. Godfred-Cato S, Bryant B, Leung J, et al;
California MIS-C Response Team.
COVID-19-associated multisystem inflammatory
syndrome in children: United States, March-July
2020. MMWR Morb Mortal Wkly Rep. 2020;69(32):
1074-1080. doi:10.15585/mmwr.mm6932e2
15. Castagnoli R, Votto M, Licari A, et al. Severe
acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection in children and adolescents:
a systematic review. JAMA Pediatr. 2020;174(9):
882-889. doi:10.1001/jamapediatrics.2020.1467
16. Office of the Federal Register; Government
Publishing Office. Electronic code of federal




17. Centers for Disease Control and Prevention.
Partner updates: case definition for MISC-C.
Accessed December 4, 2020. https://www.cdc.gov/
mis-c/hcp/
18. Leteurtre S, Duhamel A, Grandbastien B, et al.
Daily estimation of the severity of multiple organ
dysfunction syndrome in critically ill children. CMAJ.
2010;182(11):1181-1187. doi:10.1503/cmaj.081715
19. World Health Organization. Haemoglobin
concentrations for the diagnosis of anaemia and
assessment of severity. Accessed February 4, 2021.
https://www.who.int/vmnis/indicators/
haemoglobin.pdf
20. Centers for Disease Control and Prevention.
Defining childhood obesity: BMI for children and
teens. Accessed September 21, 2020. https://www.
cdc.gov/obesity/childhood/defining.html
21. Lopez L, Colan SD, Frommelt PC, et al.
Recommendations for quantification methods
during the performance of a pediatric
echocardiogram: a report from the Pediatric
Measurements Writing Group of the American
Society of Echocardiography Pediatric and
Congenital Heart Disease Council. J Am Soc
Echocardiogr. 2010;23(5):465-495. doi:10.1016/j.
echo.2010.03.019
22. McCrindle BW, Rowley AH, Newburger JW,
et al; American Heart Association Rheumatic Fever,
Endocarditis, and Kawasaki Disease Committee of
the Council on Cardiovascular Disease in the Young;
Council on Cardiovascular and Stroke Nursing;
Council on Cardiovascular Surgery and Anesthesia;
and Council on Epidemiology and Prevention.
Diagnosis, treatment, and long-term management
of Kawasaki disease: a scientific statement for
health professionals from the American Heart
Association. Circulation. 2017;135(17):e927-e999.
doi:10.1161/CIR.0000000000000484
23. Matics TJ, Sanchez-Pinto LN. Adaptation and
validation of a pediatric Sequential Organ Failure
Assessment Score and evaluation of the Sepsis-3
Definitions in Critically Ill Children. JAMA Pediatr.
2017;171(10):e172352. doi:10.1001/jamapediatrics.
2017.2352
24. Linkins LA, Dans AL, Moores LK, et al.
Treatment and prevention of heparin-induced
thrombocytopenia: Antithrombotic Therapy and
Prevention of Thrombosis, 9th ed: American
College of Chest Physicians evidence-based clinical
practice guidelines. Chest. 2012;141(2)(suppl):
e495S-e530S. doi:10.1378/chest.11-2303
25. Spiegelman D, Hertzmark E. Easy SAS
calculations for risk or prevalence ratios and
differences. Am J Epidemiol. 2005;162(3):199-200.
doi:10.1093/aje/kwi188
26. Norton EC, Miller MM, Kleinman LC. Computing
adjusted risk ratios and risk differences in Stata. The
Stata Journal. 2013;13(3):492-509.
27. Lee EH, Kepler KL, Geevarughese A, et al.
Race/ethnicity among children with
COVID-19-associated multisystem inflammatory
syndrome. JAMA Netw Open. 2020;3(11):e2030280.
doi:10.1001/jamanetworkopen.2020.30280
28. Portman MA, Dahdah NS, Slee A, et al; EATAK
Investigators. Etanercept with IVIg for acute
Kawasaki disease: a randomized controlled trial.
Pediatrics. 2019;143(6):e20183675. doi:10.1542/peds.
2018-3675
29. Clark DE, Denby KJ, Kaufman LM, et al.
Predictors of intravenous immunoglobulin
nonresponse and racial disparities in Kawasaki
disease. Pediatr Infect Dis J. 2018;37(12):1227-1234.
doi:10.1097/INF.0000000000002019
30. Matsubara D, Kauffman HL, Wang Y, et al.
Echocardiographic findings in pediatric multisystem
inflammatory syndrome associated with COVID-19
in the United States. J Am Coll Cardiol. 2020;76(17):
1947-1961. doi:10.1016/j.jacc.2020.08.056
31. Belhadjer Z, Méot M, Bajolle F, et al. Acute heart
failure in multisystem inflammatory syndrome in
children in the context of global SARS-CoV-2
pandemic. Circulation. 2020;142(5):429-436. doi:
10.1161/CIRCULATIONAHA.120.048360
32. Theocharis P, Wong J, Pushparajah K, et al.
Multimodality cardiac evaluation in children and
young adults with multisystem inflammation
associated with COVID-19. Eur Heart J Cardiovasc
Imaging. 2020;jeaa212. doi:10.1093/ehjci/jeaa212
33. Freaney PM, Shah SJ, Khan SS. COVID-19 and
heart failure with preserved ejection fraction. JAMA.
2020. doi:10.1001/jama.2020.17445
34. Muniz JC, Dummer K, Gauvreau K, Colan SD,
Fulton DR, Newburger JW. Coronary artery
dimensions in febrile children without Kawasaki
disease. Circ Cardiovasc Imaging. 2013;6(2):239-244.
doi:10.1161/CIRCIMAGING.112.000159
35. Shulman ST, Rowley AH. Kawasaki disease:
insights into pathogenesis and approaches to
treatment. Nat Rev Rheumatol. 2015;11(8):475-482.
doi:10.1038/nrrheum.2015.54
36. Alsaied T, Tremoulet AH, Burns JC, et al.
Review of cardiac involvement in multisystem
inflammatory syndrome in children. Circulation.
2021;143(1):78-88. doi:10.1161/CIRCULATIONAHA.
120.049836
37. Guo T, Fan Y, Chen M, et al. Cardiovascular
implications of fatal outcomes of patients with
coronavirus disease 2019 (COVID-19). JAMA Cardiol.
2020;5(7):811-818. doi:10.1001/jamacardio.2020.
1017
38. Rowley AH. Understanding SARS-CoV-2-
related multisystem inflammatory syndrome in
children. Nat Rev Immunol. 2020;20(8):453-454.
doi:10.1038/s41577-020-0367-5
39. Lee PY, Day-Lewis M, Henderson LA, et al.
Distinct clinical and immunological features of
SARS-CoV-2-induced multisystem inflammatory
syndrome in children. J Clin Invest. 2020;130(11):
5942-5950. doi:10.1172/JCI141113
40. Belhadjer Z, Auriau J, Méot M, et al. Addition of
corticosteroids to immunoglobulins is associated
with recovery of cardiac function in
multi-inflammatory syndrome in children. Circulation.
2020;142(23):2282-2284. doi:10.1161/
CIRCULATIONAHA.120.050147
Research Original Investigation Characteristics and Outcomes of US Children and Adolescents With MIS-C Compared With Severe Acute COVID-19
E14 JAMA Published online February 24, 2021 (Reprinted) jama.com
© 2021 American Medical Association. All rights reserved.
